Zahraa Abdul Sater1, Abhishek Jha2, Ahmed Hamimi1, Adel Mandl1, Iris R Hartley3, Sriram Gubbi1, Mayank Patel2, Melissa Gonzales2, David Taïeb4, Ali Cahid Civelek5,6, Ahmed M Gharib1, Sungyoung Auh1, Alana E O'Mara1, Karel Pacak2, Aaron M Cypess1. 1. National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland. 2. Section on Medical Neuroendocrinology, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 3. Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, Maryland. 4. Department of Nuclear Medicine, La Timone University Hospital, CERIMED, Aix-Marseille University, Marseille, France. 5. Nuclear Medicine Division, Radiology, and Imaging Sciences, Warren Grant Magnuson Clinical Center, National Institutes of Health, Bethesda, Maryland. 6. Nuclear Medicine, Radiology and Radiological Science, Johns Hopkins Medicine, Baltimore, Maryland.
Abstract
CONTEXT: Pheochromocytomas/paragangliomas (PPGLs) are neuroendocrine tumors that can secrete norepinephrine (NE). Brown adipose tissue (BAT) activation is mediated through the action of NE on β-adrenoceptors (β-ARs). In some malignancies, BAT activation is associated with higher cancer activity. OBJECTIVE: To study the relationship between BAT activation and PPGL clinical outcomes. DESIGN: A retrospective case-control study that included 342 patients with PPGLs who underwent 18F-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography (18F-FDG PET/CT) imaging at the National Institutes of Health (NIH). We excluded all patients with parasympathetic tumors and those who underwent 18F-FDG PET/CT after PPGL resection. Scans of 205 patients were reviewed by 2 blinded nuclear medicine physicians; 16 patients had BAT activation on 18F-FDG PET/CT [7.80%; age 27.50 (15.00-45.50) years; 10 female/6 male; body mass index [BMI] 24.90 [19.60-25.35] kg/m2). From the remaining 189 patients, we selected 36 matched controls (age 34.4 [25.4-45.5] years; 21 female/15 male; BMI 25.0 [22.0-26.0] kg/m2). PRIMARY OUTCOME MEASURE: Overall survival. RESULTS: The presence of active BAT on 18F-FDG PET/CT was associated with decreased overall survival when compared with the control group (HRz 5.80; 95% CI, 1.05-32.05; P = 0.02). This association remained significant after adjusting for the SDHB mutation. Median plasma NE in the BAT group was higher than the control group [4.65 vs 0.55 times above the upper limit of normal; P < 0.01]. There was a significant association between higher plasma NE levels and mortality in PPGLs in both groups. CONCLUSIONS: Our findings suggest that the detection of BAT activity in PPGL patients is associated with higher mortality. We suggest that BAT activation could either be reflecting or contributing to a state of increased host stress that may predict poor outcome in metastatic PPGL. Published by Oxford University Press on behalf of the Endocrine Society 2020.
CONTEXT: Pheochromocytomas/paragangliomas (PPGLs) are neuroendocrine tumors that can secrete norepinephrine (NE). Brown adipose tissue (BAT) activation is mediated through the action of NE on β-adrenoceptors (β-ARs). In some malignancies, BAT activation is associated with higher cancer activity. OBJECTIVE: To study the relationship between BAT activation and PPGL clinical outcomes. DESIGN: A retrospective case-control study that included 342 patients with PPGLs who underwent 18F-fluoro-2-deoxy-D-glucose positron emission tomography-computed tomography (18F-FDG PET/CT) imaging at the National Institutes of Health (NIH). We excluded all patients with parasympathetic tumors and those who underwent 18F-FDG PET/CT after PPGL resection. Scans of 205 patients were reviewed by 2 blinded nuclear medicine physicians; 16 patients had BAT activation on 18F-FDG PET/CT [7.80%; age 27.50 (15.00-45.50) years; 10 female/6 male; body mass index [BMI] 24.90 [19.60-25.35] kg/m2). From the remaining 189 patients, we selected 36 matched controls (age 34.4 [25.4-45.5] years; 21 female/15 male; BMI 25.0 [22.0-26.0] kg/m2). PRIMARY OUTCOME MEASURE: Overall survival. RESULTS: The presence of active BAT on 18F-FDG PET/CT was associated with decreased overall survival when compared with the control group (HRz 5.80; 95% CI, 1.05-32.05; P = 0.02). This association remained significant after adjusting for the SDHB mutation. Median plasma NE in the BAT group was higher than the control group [4.65 vs 0.55 times above the upper limit of normal; P < 0.01]. There was a significant association between higher plasma NE levels and mortality in PPGLs in both groups. CONCLUSIONS: Our findings suggest that the detection of BAT activity in PPGL patients is associated with higher mortality. We suggest that BAT activation could either be reflecting or contributing to a state of increased host stress that may predict poor outcome in metastatic PPGL. Published by Oxford University Press on behalf of the Endocrine Society 2020.
Authors: Mark J W Hanssen; Joris Hoeks; Boudewijn Brans; Anouk A J J van der Lans; Gert Schaart; José J van den Driessche; Johanna A Jörgensen; Mark V Boekschoten; Matthijs K C Hesselink; Bas Havekes; Sander Kersten; Felix M Mottaghy; Wouter D van Marken Lichtenbelt; Patrick Schrauwen Journal: Nat Med Date: 2015-07-06 Impact factor: 53.440
Authors: Anna Yordanova; Karin Mayer; Peter Brossart; Maria A Gonzalez-Carmona; Christian P Strassburg; Markus Essler; Hojjat Ahmadzadehfar Journal: Eur J Nucl Med Mol Imaging Date: 2017-03-01 Impact factor: 9.236
Authors: Troy Puar; Anouk van Berkel; Martin Gotthardt; Bas Havekes; Ad R M M Hermus; Jacques W M Lenders; Wouter D van Marken Lichtenbelt; Ying Xu; Boudewijn Brans; Henri J L M Timmers Journal: J Clin Endocrinol Metab Date: 2015-11-17 Impact factor: 5.958
Authors: Evanna L Mills; Kerry A Pierce; Mark P Jedrychowski; Ryan Garrity; Sally Winther; Sara Vidoni; Takeshi Yoneshiro; Jessica B Spinelli; Gina Z Lu; Lawrence Kazak; Alexander S Banks; Marcia C Haigis; Shingo Kajimura; Michael P Murphy; Steven P Gygi; Clary B Clish; Edward T Chouchani Journal: Nature Date: 2018-07-18 Impact factor: 49.962
Authors: Lucas de Pádua Gomes de Farias; Gustavo Borges da Silva Teles; Luciana de Pádua Silva Baptista; Andrei Skromov de Albuquerque Journal: Radiol Cardiothorac Imaging Date: 2022-07-28
Authors: S Severi; A Bongiovanni; M Ferrara; S Nicolini; F Di Mauro; M Sansovini; I Lolli; E Tardelli; C Cittanti; V Di Iorio; E Mezzenga; E Scarpi; T Ibrahim; G Paganelli; S Zovato Journal: ESMO Open Date: 2021-06-14